Iridinesulfonamide compound and use method thereof
AssigneesChia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.
InventorsLi Zhu, Yanqing Yang, Liguang Dai, Xiaowei Duan, Zhao Yang, Hui Zhang, Yuandong Hu, Yong Peng, Yongxin Han, Rui Zhao, Xin Tian, Shanchun Wang
Life of this patent
Estimating the term…
Abstract
An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer.
Claims16
A compound of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof,
- wherein,
- W is —(X1)p—(X2)q—(X3)r—;
- X1 is selected from C1-6 alkylene, which is optionally substituted with one or more groups independently selected from R5;
- X2 is selected from pyrrolidinyl, cyclobutyl or azetidinyl;
- X3 is selected from —NR7—;
- p is 0 or 1;
- q is 0 or 1;
- r is 0 or 1;
- and p, q, r are not 0 simultaneously;
- R1 is selected from C3-6 cycloalkyl or C3-6 heterocycloalkyl, which is optionally substituted with one or more groups independently selected from R8;
- R2 is selected from phenyl or pyridyl, which is optionally substituted with one or more groups independently selected from R9;
- each of R3 and R4 is independently selected from halogen, amino, hydroxyl, halogenated C1-3 alkyl or C1-6 alkyl;
- R5 and R8 are each independently selected from halogen, amino, hydroxyl, cyano, halogenated C1-3 alkyl, C1-6 alkyl or C3-6 cycloalkyl;
- R7 is selected from hydrogen, C1-3 alkyl or amino protecting group;
- R9 is selected from halogen, amino, hydroxyl, cyano, halogenated C1-3 alkyl or aminosulfonyl;
- m is 0 or 1;
- n is 0 or 1.
Dependencies are inferred from the claim text.